Trialbee, a privately held patient enrollment company, has sweetened its clinical trial offering with the rollout of Honey Omnichannel that tracks multiple recruitment sources.
The Sweden-based company’s multichannel approach also offers sponsors and CROs a simpler patient path with consistent messaging and pre-qualification. The tool reduces the burden of managing referrals at research sites while providing real-time analytics for all global recruitment activities and allows study teams to drive better enrollment and diversity outcomes for their trial, the company said in a press release.
Trialbee unveiled Honey Omnichannel at the CNS Summit held in mid-November.
The company said Honey Omnichannel will be launched with lupus as the pilot indication because of the complexity of the disease and its unique patient populations that pose a challenge to clinical trials looking to increase diversity in recruiting. Lupus disproportionately affects women who identify as African American, Hispanic, Asian, and Native American.
“Omnichannel ensures those impacted by lupus are aware of clinical trials before making a decision,” the company said in its Nov. 16 press release. “With more than 100 interventional clinical trials for lupus in recruitment and more in the pipeline, Trialbee is bringing together partners who know how to engage with people living with lupus across the spectrum of ethnicity, race, education, age, geography, attitude, and access.”
The company, which is headquartered in Malmö, Sweden, launched its flagship Trialbee Honey product in 2021 that tracks and measures recruitment activities while streamlining enrollment timelines by using real-time analytics.
Earlier this year, Trialbee said it expected further growth this year and beyond due to increased demand for data-driven services to improve patient recruitment.